GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (AMEX:CANF) » Definitions » Equity-to-Asset
中文

Can Fite Biofarma (Can Fite Biofarma) Equity-to-Asset : 0.63 (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Can Fite Biofarma Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Can Fite Biofarma's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $6.24 Mil. Can Fite Biofarma's Total Assets for the quarter that ended in Dec. 2023 was $9.99 Mil. Therefore, Can Fite Biofarma's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.63.

The historical rank and industry rank for Can Fite Biofarma's Equity-to-Asset or its related term are showing as below:

CANF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.3   Med: 0.61   Max: 0.71
Current: 0.63

During the past 13 years, the highest Equity to Asset Ratio of Can Fite Biofarma was 0.71. The lowest was 0.30. And the median was 0.61.

CANF's Equity-to-Asset is ranked worse than
52.49% of 1564 companies
in the Biotechnology industry
Industry Median: 0.66 vs CANF: 0.63

Can Fite Biofarma Equity-to-Asset Historical Data

The historical data trend for Can Fite Biofarma's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Can Fite Biofarma Equity-to-Asset Chart

Can Fite Biofarma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.30 0.64 0.71 0.48 0.63

Can Fite Biofarma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.48 0.63 0.62 0.57 0.63

Competitive Comparison of Can Fite Biofarma's Equity-to-Asset

For the Biotechnology subindustry, Can Fite Biofarma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Can Fite Biofarma's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Can Fite Biofarma's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Can Fite Biofarma's Equity-to-Asset falls into.



Can Fite Biofarma Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Can Fite Biofarma's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=6.243/9.989
=0.62

Can Fite Biofarma's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=6.243/9.989
=0.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Can Fite Biofarma  (AMEX:CANF) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Can Fite Biofarma Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Can Fite Biofarma's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Can Fite Biofarma (Can Fite Biofarma) Business Description

Traded in Other Exchanges
Address
10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva, ISR, 4951778
Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Can Fite Biofarma (Can Fite Biofarma) Headlines

From GuruFocus

Can-Fite BioPharma Announces $6 Million Registered Direct Offering

By Marketwired Marketwired 05-20-2019